Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Who May Be Eligible (Plain English)

Who May Qualify: - Paediatric and adult male patients - On-demand and prophylactic patients with haemophilia A (any severity) - Only previously treated patients (previous FVIII replacement therapy) will be included in the study Who Should NOT Join This Trial: - Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease - Patients with documented presence of any FVIII inhibitor Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Paediatric and adult male patients * On-demand and prophylactic patients with haemophilia A (any severity) * Only previously treated patients (previous FVIII replacement therapy) will be included in the study Exclusion Criteria: * Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease * Patients with documented presence of any FVIII inhibitor

Treatments Being Tested

DRUG

Turoctocog alfa

Turoctocog alfa was administered intravenously.

Locations (7)

National centre for Hamophilia
Baghdad, Iraq
Novo Nordisk Investigational Site
Baghdad, Iraq
Basrah Haemoplhilia centre
Basra, Iraq
Hilla Haemophilia centre
Hillah, Iraq
Karbala Haemophilia centre
Karbala, Iraq
Kirkuk Centre for Cancer and Blood Disorders
Kirkuk, Iraq
Najaf Haemophilia Centre
Najaf, Iraq